Home

abbattere Fusione Nazionale stada arzneimittel investor relations lol Tenere Pigmalione

Financial Reports - Investor Relations | STADA
Financial Reports - Investor Relations | STADA

Annual Report 2022 | STADA
Annual Report 2022 | STADA

Annual General Meeting 2020 - Investor Relations | STADA
Annual General Meeting 2020 - Investor Relations | STADA

Hemofarm - News - STADA Health Report 2023: Mental Health of Europeans Is  Improving
Hemofarm - News - STADA Health Report 2023: Mental Health of Europeans Is Improving

Farmaceutica: il Gruppo STADA continua a crescere anche in tempi difficili
Farmaceutica: il Gruppo STADA continua a crescere anche in tempi difficili

STADA Arzneimittel AG - Slide-show-presentation-1T | PDF | Generic Drug |  Investor
STADA Arzneimittel AG - Slide-show-presentation-1T | PDF | Generic Drug | Investor

Investor Relations | STADA
Investor Relations | STADA

STADA shows resilience with double-digit growth in 2020 | STADA
STADA shows resilience with double-digit growth in 2020 | STADA

IR Contact - Investor Relations | STADA
IR Contact - Investor Relations | STADA

Corporate Presentation Investor Relations, May 2015
Corporate Presentation Investor Relations, May 2015

Persona che tiene il cellulare con il logo della società tedesca Stada  Arzneimittel AG sullo schermo di fronte alla pagina web aziendale. Messa a  fuoco sul display del telefono Foto stock -
Persona che tiene il cellulare con il logo della società tedesca Stada Arzneimittel AG sullo schermo di fronte alla pagina web aziendale. Messa a fuoco sul display del telefono Foto stock -

Press release: STADA ranks among top 10% of pharma firms on sustainability  | Presseportal
Press release: STADA ranks among top 10% of pharma firms on sustainability | Presseportal

Ad hoc Releases - Stock - Investor Relations | STADA
Ad hoc Releases - Stock - Investor Relations | STADA

Nidda Healthcare GmbH - Investor Relations
Nidda Healthcare GmbH - Investor Relations

Investor Relations | STADA
Investor Relations | STADA

STADA_Press Conference_Invitation_2023.pdf | STADA Arzneimittel AG
STADA_Press Conference_Invitation_2023.pdf | STADA Arzneimittel AG

Hemofarm - News - STADA's 2021 above-market development strengthens base  for further growth, especially in Consumer Healthcare and Specialty
Hemofarm - News - STADA's 2021 above-market development strengthens base for further growth, especially in Consumer Healthcare and Specialty

Investor Relations | STADA
Investor Relations | STADA

Annual Report 2022 | STADA
Annual Report 2022 | STADA

Investor Relations | STADA
Investor Relations | STADA

STADA Arzneimittel AG - Slide-show-presentation-1T | PDF | Generic Drug |  Investor
STADA Arzneimittel AG - Slide-show-presentation-1T | PDF | Generic Drug | Investor

IR Contact - Investor Relations | STADA
IR Contact - Investor Relations | STADA

STADA's excellent results in H1 2023 | STADA
STADA's excellent results in H1 2023 | STADA

STADA and Alvotech broaden European patients' options by launching  Hukyndra® high-concentration, citrate-free adalimumab - Alvotech
STADA and Alvotech broaden European patients' options by launching Hukyndra® high-concentration, citrate-free adalimumab - Alvotech